Overview

Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy

Status:
Terminated
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
Hormonal therapy administered before surgery in ER-positive and HER2-positive patients with breast cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Western Regional Medical Center
Treatments:
Docetaxel
Fulvestrant
Pertuzumab
Trastuzumab